Tezspire Phase III EoE Results Reported by Amgen and AstraZeneca

Phase III CROSSING results announced

Amgen and AstraZeneca announced full results from the Phase III CROSSING trial of Tezspire, also known as tezepelumab, in eosinophilic esophagitis, according to Thepharmaletter.

Thepharmaletter reported that the trial showed strong and sustained efficacy through 52 weeks over current standard therapy in adults and adolescent patients with eosinophilic esophagitis, or EoE.

The announcement concerns Tezspire in a disease area that could represent a new indication for the therapy. Thepharmaletter described the findings as Phase III results from CROSSING and identified Amgen and AstraZeneca as the companies behind the announcement.

Reported evidence in EoE

According to Thepharmaletter, the reported efficacy was sustained through 52 weeks. The comparison cited in the report was current standard therapy, and the patient population included adults and adolescents.

For pharmaceutical and biotech sales professionals, the update centers on the reported Phase III evidence for tezepelumab in EoE. The announcement gives the companies a new clinical-results communication point focused on sustained efficacy, the study comparison, and the adult and adolescent populations named in the report.

Key details from Thepharmaletter

• Amgen and AstraZeneca announced full Phase III CROSSING results.
• The results concerned Tezspire, or tezepelumab, in eosinophilic esophagitis.
• Thepharmaletter reported strong and sustained efficacy through 52 weeks.
• The reported comparison was against current standard therapy.
• The trial included adult and adolescent patients.

Potential indication expansion

Thepharmaletter reported that the results support Tezspire’s potential expansion into a new, third indication. The report did not present this potential expansion as an established indication.

The update places the CROSSING trial at the center of the companies’ EoE communication. Sales professionals following the announcement can distinguish between the disclosed Phase III findings and the reported potential for a third indication.

Thepharmaletter characterized the announcement as strong Phase III results for Tezspire in EoE, with efficacy reported as sustained through 52 weeks over current standard therapy.